Enwei Pharmaceutical Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Yongjiang Xue
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 6.9yrs |
| CEO ownership | n/a |
| Management average tenure | 6.9yrs |
| Board average tenure | 6.9yrs |
CEO
Yongjiang Xue (53 yo)
6.9yrs
Tenure
CN¥1,398,000
Compensation
Mr. Yongjiang Xue is Chairman & CEO of Enwei Pharmaceutical Co., Ltd. Since 2018, and serves as its Director.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice Chairman & President | 6.9yrs | CN¥726.00k | no data | |
| CFO, VP & Secretary of the Board | 5.9yrs | CN¥443.70k | no data | |
| VP & Director | 6.9yrs | CN¥422.00k | no data | |
| Vice President | 6.8yrs | CN¥471.00k | no data | |
| Chairman & CEO | 6.9yrs | CN¥1.40m | no data |
6.9yrs
Average Tenure
51yo
Average Age
Experienced Management: 301331's management team is seasoned and experienced (6.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice Chairman & President | 6.9yrs | CN¥726.00k | no data | |
| VP & Director | 6.9yrs | CN¥422.00k | no data | |
| Chairman & CEO | 6.9yrs | CN¥1.40m | no data | |
| Independent Director | 6.7yrs | CN¥100.00k | no data | |
| Director | 6.9yrs | CN¥1.40m | no data | |
| Independent Director | 6.9yrs | CN¥100.00k | no data | |
| Independent Director | 6.7yrs | no data | no data | |
| Chairman of Board of Supervisors | 6.9yrs | no data | no data | |
| Supervisor | 6.9yrs | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data |
6.9yrs
Average Tenure
53yo
Average Age
Experienced Board: 301331's board of directors are considered experienced (6.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 10:24 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Enwei Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|